Insights on the Hypoxia Inducible Factor Alpha inhibitor Market to 2027 | Industry Statistics, Emerging Demands, Forecast to 2027

The global hypoxia inducible factor alpha inhibitor market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Hypoxia-inducible factors (HIFs) are transcript factors responding to reductions in presented oxygen in the cellular environment or hypoxia. The major factor driving the growth of the market is the increasing prevalence of cancer across the globe. According to the National Cancer Institute (NCI), it was estimated that 1,806,590 new cases of cancer will be diagnosed in the US with a mortality rate of 606,520 people in 2020. Furthermore, there were 18.1 million new cases and 9.5 million cancer-related mortalities globally in 2018 which is anticipated to rise to 29.5 million and the number of cancer-related mortalities to 16.4 million by 2040. Hence, the rising prevalence of cancer is driving the demand for hypoxia inducible factor alpha inhibitors. The HIF-alpha is a major regulator of tumor angiogenesis. Histone deacetylase (HDAC) and Mammalian target of rapamycin (mTOR) inhibitors suppress tumor-induced angiogenesis by reducing tumor HIF-1 alpha protein expression.

To Request a Sample of our Report on Hypoxia Inducible Factor Alpha inhibitor Market: https://www.omrglobal.com/request-sample/hypoxia-inducible-factor-alpha-inhibitor-market

Some major players operating in the market include Merck & Co., Inc., and Astellas Pharma Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in August 2021, Merck announced the approval of WELIREG from the US Food and Drug Administration (FDA). It is an oral hypoxia-inducible factor-2 alpha (HIF-2?) inhibitor that is used for the treatment of adult patients with von Hippel-Lindau (VHL) disease.

Market Coverage

· The market number available for - 2020-2027

· Base year- 2020

· Forecast period- 2021-2027

Segment Covered-

· By Type

· By Application

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Merck & Co., Inc., and Astellas Pharma Inc., among others.

(Get 15% Discount on Buying this Report)

A full Report of Hypoxia Inducible Factor Alpha inhibitor Market is Available @ https://www.omrglobal.com/industry-reports/hypoxia-inducible-factor-alpha-inhibitor-market

Global Hypoxia Inducible Factor Alpha Inhibitor Market Report by Segment

By Type

· HIF-1?

· HIF-2?

· HIF-3?

By Application

· Solid Tumor

· Acute Myelocytic Leukemia

· Cancer

· Others

Global Hypoxia Inducible Factor Alpha Inhibitor Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.